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 Biochemical Markers and Genetic Risk Factors in Canine Tumors 
Abstract  
One out of four dogs will develop cancer before the age of 10 years. Many of them 
will succumb to the disease. Risk factor analysis, tumor prevention, and ways to 
prognosticate already existing tumors in the individual patient, are important. 
Canine mammary tumors (CMT) are the most common type of tumor in intact 
female dogs and constitute about half of all tumors in female dogs. About half of the 
CMT are malignant. The origin of CMT is considered to be complex, with tumor 
development likely influenced by both genetic and environmental factors. In 
Sweden 36% of English Springer spaniels (ESS) are diagnosed with CMT, 
suggesting a genetic influence in this breed. Several risk factors predisposing to 
CMT have been identified, but the majority of inherited risk factors remain 
unknown.  
The aim of the research described in this thesis was to study biomarkers, 
epidemiology and genetic risk factors in canine tumors with the main focus in 
canine mammary tumors, using a population of a breed at high-risk for this disease 
in Sweden. In the first study, a study of a serum biomarker in canine tumors, serum 
thymidine kinase 1 (TK1) -activity in canine malignant lymphoma, leukemia and 
solid tumors using the standard TK REA and non-radiometric assays was 
performed. Serum TK1 was proven to be highly effective in diagnosing, 
prognosticating, and monitoring dogs with hematological neoplasias (lymphoma, 
leukemia), but the assay was ineffective in detecting TK1 activity in solid tumors 
such as CMT. Clinical and histological characteristics of CMT were described in a 
population of ESS dogs in Sweden. The reproductive status was shown as an 
important risk factor for MT development and age of onset and histological subtype 
affected the survival time after diagnosis of MT-affected dogs. Genetic risk factors 
for CMT were further investigated in the following studies. A candidate gene 
association study in CMT showed two human breast cancer genes, BRCA1 and 
BRCA2 that were associated with CMT in ESS dogs. The potential involvement of 
the major histocompatibility complex (MHC) class II in CMT development was 
studied and the results indicated diversity of MHC class II haplotypes and identified 
a haplotype that protected against MT development in ESS dogs.  
In summary, this thesis provides new information about risk factors for CMT 
development. The identification of genetic risk factors is critical to improvements in 
prevention, diagnosis and treatment of these tumors. 
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1 Introduction 
The problem of cancer in dogs (Canis familiaris) is a serious challenge that 
veterinarians frequently face. It is estimated that one of four dogs greater 
than 2 years of age dies of cancer, and certain popular breeds are 
overrepresented in terms of cancer incidence and mortality (Olson, 2007; 
Khanna et al., 2006). The prevalence of cancer in dogs has increased in 
recent years.  
Advances in the care of animals have allowed dogs to live longer because 
of better nutrition, vaccination for common infectious diseases, leash laws 
that limit automobile deaths, and the availability of more sophisticated 
diagnostics and treatments for many ailments previously considered to be 
life-threatening. This improved general health of pets has resulted in an 
increase in age-related diseases including cancer (Paoloni & Khanna, 2007).  
Companion dogs develop tumors spontaneously, are relatively inbred and 
immunologically competent, and share their living environment with 
humans. Spontaneous tumors in companion animals represent a valuable and 
underutilized resource in cancer research. The complex interaction between 
tumor and host microenvironment associated with tumor development and 
progression may therefore be effectively captured in these natural models, 
and as such, provide unique insights into tumor biology. Mammary tumors 
are one of the most common types of neoplasia affecting intact female dogs 
(Egenvall et al., 2005; Moe, 2001; Moulton et al., 1986; Priester & Mantel, 
1971; Dorn et al., 1968b; Fidler & Brodey, 1967). Mammary tumors (MT) 
constitute about half of all tumors in intact female dogs, and the proportion 
of malignant tumors is around 50% (Gilbertson et al., 1983; Moulton et al., 
1970). Previous studies have identified many similarities between canine 
mammary tumors (CMT) and breast cancer in women, in terms of 
epidemiology, biology, dietary risk factors, and clinical behavior, as well as 
hormonal dependence (Sorenmo, 2003; Frese, 1985; Chrisp & Spangler, 
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1980). It has been suggested that the origin of CMT is multifactorial and 
depends on an interaction between multiple major and minor genetic risk 
factors and environmental factors. Several risk factors predisposing to CMT 
have been identified, but the majority of inherited risk factors remain 
unknown. The overall aim and main focus of the research described in this 
thesis was to study biomarkers, epidemiology and genetic risk factors in 
canine tumors with the main focus in canine mammary tumors (CMT) 
using a population of a breed at high-risk for this disease in Sweden. 
Common concepts in the field of CMT are summarized in chapter 2. The 
subsequent chapters (3-7) describe and discuss the four studies included in 
the thesis. 
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2 Canine mammary tumors 
2.1 Incidence of canine mammary tumors in Sweden 
Mammary tumors are the most common form of neoplasia affecting female 
dogs (Bonnett et al., 2005). Breast cancer is often familiar in humans, but a 
similar hereditary pattern has not been described for MT in dogs, although 
breed predilections have been reported (Egenvall et al., 2005; Cotran, 1994; 
Dorn et al., 1968b). High-risk breeds vary, depending on study and 
geographic location. Several spaniel breeds, the Doberman, the German 
shepherd and the Boxer are predisposed to MT in the Swedish dog 
population (Egenvall et al., 2005). The ESS breed has the second highest 
incidence of MT among all dog breeds in Sweden, with 319 dogs per 
10,000 years at risk, which represents a hazard ratio of 2.7 compared to the 
general dog population (Egenvall et al., 2005).  
 The onset of MT is believed to be influenced by age, hormones, and 
genetic predisposition. MT are rarely seen in young dogs (<3 years of age) 
(Egenvall et al., 2005); however, benign cystic hyperplasia can be seen in 
dogs, involving all mammary glands. Most MT arise in middle-aged intact 
females, with a peak incidence between 6 and 10 years of age (Egenvall et 
al., 2005). The median age of occurrence of CMT is reported to be 10-11 
years; however, some breeds develop MT at a younger age (Moe, 2001; 
Boldizsar et al., 1992; Priester, 1979). Studies of age-specific incidence rates 
have found a higher incidence in old, than in young, bitches (Dorn et al., 
1968a). The ESS has been shown to have a relatively low median age of 
onset at 6.9 years of age in the Swedish dog population aged 3-10 years 
(Egenvall et al., 2005). MT in males is rare (<1% of all MT occur in males), 
and female dogs are 62 times more likely to develop MT than male dogs 
(Saba et al., 2007).  
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The life-time incidence of MT is reported to be 0.5% in female dogs spayed 
before their first estrus cycle, but increases to 8% or 26% if spayed after the 
first or second estrus, respectively (Schneider et al., 1969). If the dog is 
spayed later than after the second estrus cycle, the risk for malignant MT is 
earlier reported to be the same as in intact bitches, although the risk for 
benign MT seems to be reduced by ovariohysterectomy (OHE) even at a 
later age (Misdorp, 1991). 
2.2 Pathogenesis of canine mammary tumors 
2.2.1 Endocrine factors 
The development of both canine and human mammary tumors is clearly 
hormone dependent (Cotran, 1994; Rutteman, 1990; Schneider et al., 
1969). The duration of exposure to sex hormones early in life influences the 
overall mammary tumor risk. Although earlier disputed, there is recent 
evidence for the importance of timing of spaying on survival time on dogs 
with mammary tumors after surgery. In a study by Sorenmo et al., dogs that 
were spayed <2 years before MT surgery had a significantly longer overall 
survival time compared to the group of intact dogs and dogs that were 
spayed >2 years before MT treatment. This result is, however, contradicted 
by other studies showing no clinical benefit with OHE at (or in proximity 
to) mastectomy (Sorenmo et al., 2000; Morris et al., 1998). The correlation 
between OHE and protection against developing MT indicates priming of 
the mammary tissue under hormonal influence. 
  Prolonged, dose-related exposure to synthetic progestins has been 
shown to induce proliferation of mammary epithelial cells, potentially 
leading to genetic errors that may subsequently result in the development of 
MT (benign and malignant) (Stovring et al., 1997; Misdorp, 1991). 
Administration of diethylstilbestrol is associated with ovarian tumor 
development, but not mammary tumors (Jabara, 1962). Prevention of heat 
by hormone administration increases the risk for mammary tumors 
(Rutteman, 1992). The risk for malignant tumors is especially increased if 
estrogen-gestagen-combinations in high doses are used (Stovring et al., 
1997; Rutteman, 1992; Misdorp, 1991). A protective effect of early 
pregnancy, well-known in humans (Costarelli & Yiannakouris, 2010; Milne 
et al., 2010), has not been demonstrated in dogs (Schneider et al., 1969).  
The exact mechanisms and interactions at the cellular level that lead to 
the development of malignant mammary tumors are unknown. Hormonal 
therapy (anti-estrogen drugs such as tamoxifen) has been shown to delay the 
onset of metastatic disease in humans with estrogen receptor-positive 
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tumors. The presence of estrogen, progesterone, and prolactin receptors on 
canine mammary tissue and tumors has been evaluated (Rutteman & 
Misdorp, 1993). About 50% of malignant primary tumors were positive for 
these receptors, and they were infrequently detected on metastatic lesions. 
2.2.2 Genetic factors 
Although hormonal influences are clearly important in MT genesis, the 
particularly high disease incidence (Egenvall et al., 2005; Rutteman & 
Misdorp, 1989) reported in certain breeds suggests a significant genetic 
component to the disease that is inherited. It is widely accepted that in 
addition to germ-line mutations, the malignant transformation requires the 
accumulation of somatic genetic alterations, or lesions. The role of acquired 
alterations in oncogenes and tumor suppressor genes is widely recognized in 
tumor formation.  
Breast cancer is often familial in humans, but a similar hereditary pattern 
has not been described for CMT, although breed predilections have been 
reported (Egenvall et al., 2005; Cotran, 1994; Dorn et al., 1968b). Women 
who have inherited mutations in the BRCA1 or BRCA2 (BRCA1/2) genes 
have substantially increased risk of breast cancer, with a lifetime risk of 56-
84% (Antoniou et al., 2006; King et al., 2003; Ford et al., 1998; Struewing et 
al., 1997). A majority of the BRCA1/2 mutations reported cause protein 
truncation through indels, nonsense mutations, splice variants, or 
rearrangements (Casilli et al., 2006; Walsh et al., 2006; Couch & Weber, 
1996; Tavtigian et al., 1996). A large number of sequence variants with 
unknown impact on the phenotype have also been detected in BRCA1/2, 
and several studies have tried to determine their clinical significance (Hofstra 
et al., 2008; Easton et al., 2007).  
Several other genes are also known to confer increased risk for breast 
cancer in humans (Walsh & King, 2007). The liability for breast cancer is 
currently believed to be a polygenic trait, where liability is conferred by a 
large number of loci, each contributing with a small effect on breast cancer 
risk (Pharoah et al., 2004). Four genes, FGFR2, LSP1, MAP3K1, and 
TOX3 were recently found to be associated with a mild increase in risk of 
breast cancer in humans in a genome-wide association study (Easton et al., 
2007). RCAS1 and TP53 have been reported to be associated with many 
types of cancer, including breast cancer (Rousseau et al., 2002). Recent 
studies in CMT found that 3 of 10 (Chu et al., 1998) and 6 of 40 (Veldhoen 
et al., 1999) primary malignant tumors contained p53 mutations, with one 
dog carrying a germ-line mutation (Veldhoen et al., 1999; Chu et al., 1998). 
In another study, 17% of 69 canine mammary carcinomas assayed showed a 
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p53 gene mutation, and multivariate analysis indicated that this mutation 
conferred an increased risk of recurrence and death from mammary tumor 
(Wakui et al., 2001). 
ERBB2 has been shown to have altered expression in human breast 
cancer and a deletion in the CHEK2 gene has been reported as associated 
with a 2-3 fold increased risk of breast cancer (Meijers-Heijboer et al., 2003; 
Meijers-Heijboer et al., 2002). 
Evidence suggests that the enzyme cyclooxygenase 2 (COX-2) also 
known as the prostaglandin H synthase plays an important role in mammary 
tumor initiation and progression in human patients (Soslow et al., 2000). 
This enzyme COX-2 catalyses the rate-limiting step in prostanoid 
biosynthesis (Hwang et al., 1998). In the dog, there is evidence of a strong 
relationship between COX-2 expression (“up-regulation”) and the 
malignancy of certain types of cancer (bladder, skin, intestinal, mammary 
and nasal)(Kleiter et al., 2004; Dore et al., 2003; McEntee et al., 2002; Pestili 
de Almeida et al., 2001; Khan et al., 2000). Cyclooxygenase 2 is usually 
absent from normal cells, but can be inducible by growth factors, 
inflammatory reactions, tumor promoters, and several oncogenes. Induction 
of COX-2 enzymes, thought to be involved in human breast cancer 
carcinogenesis, also has been evaluated in normal, benign, and malignant 
canine mammary tissue. Dore et al., found that COX-2 was not expressed 
in normal tissues, but showed increased expression in benign (24%) and 
malignant (56%) tumors, indicating a possible role in tumorigenesis (Dore et 
al., 2003). An association also has been shown between COX-2 expression 
levels and CMT histological subtype (Heller et al., 2005). Recent studies in 
CMT suggest a similar role for COX-2 in the malignant phenotype 
(Queiroga et al., 2005) and demonstrate a strong link between the level of 
COX-2 expression and the prognosis of CMT (Queiroga et al., 2009): the 
higher the expression, the poorer the prognosis.  
2.2.3 Tumor immunosurveillance 
There is evidence suggesting that the immune system has a major task in 
controlling major histocompatibility complex (MHC) class II-dependent 
immune responses directed towards tumor cells. Thus, MHC class II 
molecules have a critical role in tumor surveillance and can play a protective 
role in tumorigenesis (Ghaderi et al., 2001; Boon et al., 1994). The 
immunogenicity of a tumor antigen depends on the efficiency of the 
individual´s MHC class II molecules to present tumor antigens to T-cells. 
Consequently, tumor development will be influenced by the individual´s 
MHC class II type and which tumor antigens that are expressed. 
Considering the importance of immune surveillance during tumorigenesis 
 
 
15
(Ferguson et al., 2002; Igney & Krammer, 2002), some individuals who 
inherit specific alleles or haplotypes of the highly polymorphic human 
leukocyte antigen (HLA) genes may be predisposed to or may resist specific 
types of cancers (Wu et al., 2002; Sastre-Garau et al., 1996; Apple et al., 
1994; Bidwell et al., 1992; Pellegris et al., 1980). 
In dogs, the major histocompatibility complex is referred to as the DLA 
system and is known to contain class I, II and III genes as well as a large 
number of other genes, many which are involved in immune regulation. 
 A number of studies have been published on the role of MHC class II in 
surveillance against human breast cancer (Baccar Harrath et al., 2006; Biswal 
et al., 1998; Abrahamova & Majsky, 1988; Bouillenne & Deneufbourg, 
1979; Hammond et al., 1979; Subira et al., 1979) and for HLA class II, there 
is evidence for different alleles conferring both increased and reduced risk 
and the specific alleles vary with ethnicity (Ghaderi et al., 2001; Chaudhuri 
et al., 2000; Casoli et al., 1994). Less is known of the possible involvement 
of DLA in tumor development in dogs.  
2.2.4 Nutritional factors 
Experiments in rodents and epidemiological studies in humans have shown 
that a high-fat diet, as well as obesity, increased the risk of mammary cancer. 
A study in pet dogs in the United States found that among spayed dogs, the 
risk of developing mammary cancer was reduced if the dogs were thin at 9 
to 12 months of age OR (0.04) (Sonnenschein et al., 1991). A study in 
Spain made a similar observation, that obesity at 1 year of age was a risk 
factor for the development of benign and malignant tumors, without 
consideration of ovariectomy (Perez Alenza et al., 1998). Somewhat 
surprisingly, the intake of homemade meals (i.e., red meat) compared with 
commercial foods also was related to an increased risk. Nutritional factors, 
therefore, may play a role in CMT development (Perez Alenza et al., 2000). 
2.3 Presentation, clinical signs, and staging 
2.3.1 Clinical manifestations 
The dog generally has five pairs of mammary glands spread along the ventral 
aspect of the thorax and abdomen. The two cranial pairs are termed 
thoracic, the next two abdominal, and the most caudal are inguinal glands. 
The blood supply originates from the external pudendal arteries and the 
lateral and internal thoracic arteries. It is generally understood that lymphatic 
drainage from the thoracic and cranial abdominal glands is to the axillary and 
sternal lymph nodes, while drainage from the inguinal and caudal abdominal 
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is to the superficial inguinal nodes. However, the pathways of lymphatic 
drainage are erratic and some lymph may cross the midline. The fifth or 
inguinal neoplastic mammary gland usually drains into the ipsilateral 
superficial inguinal lymph nodes, but rarely does it also drain into the 
ipsilateral popliteal lymph node and into a lymphatic plexus at the medial 
aspect of the ipsilateral thigh (Patsikas et al., 2006). 
In the non-pregnant, non-lactating bitch the most commonly 
encountered abnormality of the mammary gland is neoplasia. Dogs with 
MT may present clinically with solitary or multiple nodules or masses within 
the mammary gland, developing simultaneously or subsequently. In the case 
of multiple nodules, each one must be treated individually. Any of the five 
pairs of glands can develop one or more benign or malignant tumors. The 
caudal mammary glands are said to be more frequently affected than the 
cranial ones, probably due to the greater volume of mammary tissue in these 
glands. Many dogs present with larger nodules. Usually, these nodules are 
firm on palpation, well circumscribed, and non-painful; they may appear 
and remain static or grow rapidly. Clinical signs of malignancy include rapid 
growth, non-circumscribed invasive growth, fixation to skin and/or 
underlying tissues, and the presence of ulceration. The presence of one or 
more of these signs is associated with an increased risk for malignancy, but 
malignancy is not excluded by their absence. It is not possible to 
differentiate benign from malignant CMT by physical examination alone. 
Carcinoma that metastasizes to the inguinal lymph nodes may enter the 
pudendal lymphatic vessels and spread to the internal iliac nodes. Metastasis 
from the internal iliac nodes may be palpable and may cause pressure on and 
compression of the colon. The other common metastatic sites include the 
lungs, kidneys, and less frequently, bones (Misdorp & Hart, 1979a; Misdorp 
& Hart, 1979b).  
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Figure 1. Clinical presentation of a simple canine mammary carcinoma before surgical 
treatment (Courtesy of Dr. von Euler). 
Diagnosing of CMT in dogs is relatively straightforward, since it can be 
made presumptively using a good clinical examination, visual inspection, 
and palpation by a veterinarian in most cases, but care should be taken to 
differentiate mammary hypertrophy and mastitis. However, histopathology 
is needed to determine grade of malignancy, which in turn influences the 
prognosis. In a study by Hellmén et al., it was shown that the disease entity 
“MT” is fairly accurately used as a clinical diagnosis in Sweden. Out of 202 
histologically and DNA-content-investigated tumors, only nine (4%) were 
considered as non-MT (four other neoplasias, and five mammary dysplasias) 
(Hellmen et al., 1993).  
2.3.2 TNM classification and clinical staging  
To stage solitary tumors, we use the TNM (tumor, node, and metastasis) 
staging system. In this system, the body is considered as three anatomical 
compartments that all have the potential to be invaded by neoplastic cells 
(T: primary tumor, N: regional lymph node, and M: distant metastasis). 
The World Health Organization`s TNM Classification of Tumors in 
Domestic animals, one of the most widely used and adapted in veterinary 
medicine, was developed to assist in determining the prognosis of mammary 
cancer (Owen, 1980). The prognosis for any individual with cancer depends 
on a number of factors: the histological type of tumor, the grade of the 
 
 
18
tumor, the clinical stage or extent of the tumor, and the presence of any 
tumor-related complications or concurrent disease. 
The clinical stage of a tumor describes the anatomical extent of a tumor 
at a set point in time, and to a large degree, this determines the feasibility of 
therapy. This TNM system takes account of the size of the primary tumor, 
the local and regional lymph nodes and distant organs where tumor 
metastases may develop. The TNM information leads to a division into four 
clinical stages, with local or regional tumor extension progressing from 
stages I to II, and distant metastasis being categorized as stage IV.  
Table 1. Clinical staging of canine malignant mammary tumors. TNM classification modified 
from LN Owen (Owen, 1980) 
T: Primary tumor size 
T1 <3 cm maximum diameter 
T2 3-5 cm maximum diameter 
T3   >5 cm maximum diameter 
T4 Inflammatory carcinoma 
N: Regional lymph nodes status 
N0  Histologic or cytologic - No metastasis present 
N1  Histologic or cytologic - Metastasis present to ipsilateral node 
N2  Histologic or cytologic - Metastasis to contralateral lymph node 
M: Distant metastasis 
M0  No distant metastasis detected 
M1  Distant metastasis detected 
Stages grouping 
I   T1    N0    M0 
II   T0-1       N1    M0 
   T2    N0-1       M0 
III  T3      Any N   M0 
      Any T     N2     M0 
IV  Any T      Any N   M1 
V   T4      Any N   Any M  
 
Determination of the clinical staging of malignant mammary tumors is 
critical to good decision-making before treatment is undertaken. Before 
considering any form of definitive therapy, it is important to clinically 
evaluate the patient; a thorough physical examination, a complete blood cell 
count, serum chemistry profile, and urinalysis are advised prior to 
performing surgery. Thoracic radiographs, including ventro-dorsal and right 
and left lateral views, are recommended for all but the smallest lesions, to 
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evaluate for potential metastasis. In one retrospective study in Sweden, it 
was shown that the likelihood of detecting pulmonary metastasis of dogs 
with MT is low in dogs <8 years of age (Djupsjobacka, 2003). The results of 
this study give reason to question the benefit of routine thoracic radiography 
of young dogs with MT. An abdominal ultrasound should be performed for 
evaluation, if abnormalities are noted on physical examination, or if blood 
work abnormalities exist.  
 
Figure 2. Lateral thorax radiograph of a female dog affected by MT that have metastasized to 
the lungs (Courtesy of Dr. von Euler). 
2.4 Histological classification of canine mammary tumors 
2.4.1 Histopathology 
Histopathological analysis after submission of the whole surgical specimen 
for evaluation by a pathologist may provide the clinician with information 
on tumor type(s), the type of growth, and the completeness of surgical 
removal. Whilst approximately half of the canine MT have been reported to 
be benign adenomas that are curable with adequate surgery (Gilbertson et 
al., 1983), about 50% are considered to be malignant and can arise from 
different structures within the mammary tissue, and half of these malignant 
tumors express the metastatic phenotype and have metastasized at the time 
of clinical presentation (Gilbertson et al., 1983; Priester & Mantel, 1971; 
Moulton et al., 1970).  
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Epithelial tumors are the most commonly diagnosed histological type of 
malignant MT, constituting more than 90 % of all MT, with the remainder 
consisting of sarcomas and mixed tumors (Gilbertson et al., 1983).  
Mammary carcinoma (adenocarcinoma) is the most common malignant 
tumor and is variously described as solid tubular or papillary. They can be 
simple (epithelium alone) or complex (epithelium and myoepithelium). The 
infiltrative characteristics of the tumor in conjunction with the degree of 
invasion into local lymphatics and capillaries are important in determining 
the long-term prognosis regarding local recurrence and metastatic potential. 
The most aggressive carcinomas have lost their identifying characteristics 
and are described as anaplastic or poorly differentiated tumors; the latter 
warrant a guarded prognosis.  
 
 
Figures 3 and 4. Anaplastic carcinoma in a canine mammary gland composed of large high 
pleomorphic cells with bizarre nuclei and showing metastasis to the regional lymph node 
ipsilateral with reactive collagenous stroma (Courtesy of Dr. Grandón). 
Inflammatory carcinomas are rare neoplasms with an extremely poor 
prognosis. These tumors can often be identified at the time of presentation.  
Malignant mixed tumors are rare tumors of the mammary gland and the 
origin within the mammary tissue is unknown. Sarcomas are considered to 
have poor prognosis; most dogs die within 9-12 months (Hellmen et al., 
1993; Misdorp et al., 1971). 
2.4.2 Histopathological classification 
Canine MT has a very detailed histopathological classification, with a 
confusing variety of different histological types of CMT described. The 
WHO histological classification aims to internationally standardize 
terminology and nomenclature of CMT with a descriptive rather than 
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histogenetic classification, to provide a system that is useful for prognosis 
(Misdorp et al,. 1999).  
Table 2. From W. Misdorp et al,: Histological classification MT of the dog and cat.  
Malignant tumors 
Noninfiltrating (in situ) carcinoma 
Complex carcinoma 
Simple carcinoma 
Tubulopapillary carcinoma 
Solid carcinoma 
Anaplastic carcinoma 
Special types of carcinomas 
Spindle cell carcinoma 
Squamous cell carcinoma 
Mucinous carcinoma 
Lipid-rich carcinoma 
Sarcoma 
Fibrosarcoma 
Osteosarcoma 
Other sarcomas 
Carcinosarcoma 
Carcinoma or sarcoma in benign tumor 
Benign tumors 
Adenoma 
Simple adenoma (epithelial or myoepithelial type) 
Complex adenoma 
Basaloid adenoma 
Fibroadenoma 
Benign mixed tumor 
Duct papilloma 
Unclassified 
Duct hyperplasia (papillomatosis/epitheliosis) 
Lobular hyperplasia 
Adenosis 
Papillomatosis/epitheliosis 
Cyst 
Ductectasia 
Local fibrosis 
Gynecomastia 
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However, with 14 different malignant types, there is a risk that the general 
practitioner can be confused. Karayannopoulou et al., in a recent study, 
evaluated the human “Elston and Ellis grading method” in dogs with 
mammary carcinomas. In this study, the authors found that histological 
grading by the Elston and Ellis method was significantly related to prognosis, 
especially in cases of simple carcinoma. (Karayannopoulou et al., 2005). 
Histological grade 0 has a 19% recurrence compared to 97% for grade II 
(Gilbertson et al., 1983). Similarly, with nuclear differentiation, poorly 
differentiated tumors had 90% recurrence, moderately differentiated had 
68%, and well differentiated, 24% (Gilbertson et al., 1983). 
In another study performed by Yamagami et al. on the prognosis for 
malignant MT in dogs based on TNM and histology classification, the 
authors found that the larger the tumor size became (T category), the poorer 
was the clinical prognosis. The same was described for the dogs with 
regional lymph node metastasis (N1, N2 category) and/or distant metastasis 
(M1 category); the survival was lower than in dogs without such 
involvement. As the grade of TNM staging increased, the prognosis was 
poorer; however, there were no significant differences in survival rates 
among subtypes of adenocarcinomas determined by WHO histological 
classification. It was also noticed in that study that dogs having carcinomas 
without tubular formation or myoepithelial cell proliferation had a lower 
survival rate than dogs having carcinomas with those characteristics, and 
invasive carcinomas into adjacent skin or lymphatic/vascular vessels implied 
a poorer prognosis than non-invasive ones. The results suggested that a 
combined practice of TNM system and the evaluation on the above 
mentioned four histologic features could be useful for prognostic 
determination of CMT (Yamagami et al., 1996).  
Moreover, Sorenmo (2009) recently described in a study the clinical and 
histological findings in dogs with MT, and compared the histological and 
clinical evidence consistent with progression from benign to malignant with 
human breast cancer epidemiology. Dogs with malignant tumors in that 
study were significantly older than dogs with benign tumors. Dogs with 
malignant tumors were significantly more likely to develop new primary 
tumors. These findings suggest that CMT progress from benign to 
malignant and that malignant tumor may be the end stage of a histological 
continuum with clinical and histopathological similarities to human breast 
cancer carcinogenesis (Sorenmo et al., 2009). 
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2.5 Treatment and prognosis 
The treatment of choice is surgical excision with appropriate margins, 
where ideally the extent of surgery (i.e., nodulectomy, mastectomy, regional 
mastectomy, unilateral or bilateral radical mastectomy) should be guided by 
clinical appearance and histological grade. The idea is to remove the entire 
tumor by the simplest surgical procedure (no clinical trial has shown 
improvement in survival with radical versus local removal). Decisions 
regarding treatment should be based on a correct TNM staging according to 
the WHO classification.  
Adjuvant treatment is common in women with breast cancer. In CMT 
there are reports of post-operative chemotherapy, radiotherapy and 
hormone level-modifying substances. In all, these studies do not show 
convincing support for combining surgery with any of these to improve 
treatment outcome. This is probably mainly due to lack of large-scale well-
controlled trials.  
Current knowledge indicates a major role for COX-2-specific inhibitors 
as part of the treatment in female dogs affected with malignant CMT.As 
many CMT do metastasize and the patients eventually die of metastatic 
disease, there is still a need for improved therapy regimens in dogs. Early 
detection and rapid therapy are essential to prevent early local or distant 
dissemination.  
2.6 Serum biochemical markers in canine tumors 
Laboratory diagnosis currently represents an integral part of patient care. 
The possibility of having strong prognostic and/or predictive markers is of 
the utmost importance for clinicians, to identify patients at higher risk of 
relapse and to select the most appropriate systemic treatment for an 
individual patient. Serum tumor markers are used to obtain prognostic 
information and to choose and monitor tumor disease treatment both in 
human and in veterinary medicine. Cellular enzyme thymidine kinase, 
determining cellular proliferation in connection with the inception, 
development, and treatment of the disease, belongs to such parameters. 
Thymidine kinase 1 (TK1) is a deoxyribonucleic acid (DNA) precursor 
enzyme that is only found in proliferating cells and is one of the key markers 
for S-phase and G2 cells in cell biology.  
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Figure 5. The role of thymidine kinase (TK) in the salvage pathway of the pyrimidine 
synthesis. TK2 is expressed in the mitochondrion and is present in the entire cell cycle. 
Leakage of TK (i.e., TK1) through the cell membrane reflects either the overall degree of 
DNA synthesis or the number of cells dying in the replicative stage. In the presence of ATP, 
TK1 catalyzes the conversion of deoxythymidine (dT) to deoxythymidine monophosphate 
(dTMP). Deoxythymidine monophosphate is subsequently phosphorylated to its triphosphate 
analogue (dTTP) before being a substrate for DNA synthesis. Illustration courtesy of Eva Hall 
(von Euler et al., 2004). 
 
A large amount of biochemical information is now available concerning the 
structure-function relationships of TK1, which have been of considerable 
interest for the antiviral and anti-cancer chemotherapy field (Al-Madhoun et 
al., 2004; Welin et al., 2004; Eriksson et al., 2002). The cell cycle and tissue 
regulation of TK1 messenger ribonucleic acid (mRNA) and protein, which 
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depends on transcriptional and posttranslational processes, has also been 
studied in great depth (Ke & Chang, 2004; Hengstschlager et al., 1994). A 
stable serum form of TK1 was identified already in 1980 and serum TK (s-
TK) levels serve as biomarker in many different malignant diseases, for 
example, Hodgkin`s and non-Hodgkin`s lymphoma (NHL), acute myeloid 
leukemia (AML), lymphocytic leukemia (LL), and chronic LL (Poley et al., 
1997; Hallek et al., 1992; Gronowitz et al., 1983). One report describes s-
TK activity and lactate dehydrogenase (LDH) activity in dogs with 
malignant lymphoma (ML) (Nakamura et al., 1997). 
More recently, s-TK radio enzyme assay (REA) determinations, 
including the use of a non-radiometric assay, were shown to provide 
prognostic and monitoring information regarding disease in canine 
malignant lymphoma (ML) (von Euler et al., 2006; von Euler et al., 2004). 
Malignant lymphoma in dogs, in particular, has been shown to share 
morphological gene expression patterns and clinical similarities with NHL in 
human patients (Sueiro et al., 2004; Teske, 1994). 
High levels of TK have been reported in human breast cancer patients 
(Romain et al., 1997; O'Neill et al., 1992a; O'Neill et al., 1992b; Spyratos et 
al., 1992). The serum TK levels in breast cancer patients demonstrated a 
statistically significant positive correlation with the cancer stage (O'Neill et 
al., 1992a). They also demonstrated that the total tumor TK levels were 
significantly higher in breast cancer patients who subsequently had a 
recurrence than in those who did not. It appears, therefore, that TK is a 
potentially useful marker in the management of breast cancer in humans 
(O'Neill et al., 1992a). Carlsson et al. recently demonstrated that the serum 
concentration of TK1 is increased in human patients with breast cancer 
(Carlsson et al., 2009). 
2.7 The dog as genetic model for complex human diseases 
The release of an annotated human genome sequence assembly and the 
emergence of genomics technologies have led to significant advances in our 
understanding of many human diseases, including cancers. As DNA 
sequencing technology has become less costly, the field of comparative 
genomics has progressed rapidly, and attention has turned now to generating 
whole genome assemblies and dedicated genomic resources for veterinary 
species. Such progress brings a whole new series of opportunities to advance 
veterinary medicine. Many human and animal diseases share a pathogenetic 
basis, and although veterinary species need advances in biomedical research 
in their own right, the consideration of companion animals as good 
 
 
26
comparative models for human disease saw the emergence of the “one 
medicine” concept. The concept of “one medicine” rests on the translation 
between human and veterinary medicine in both directions (Breen, 2009). 
The domestic dog has emerged as an ideal model for gene mapping of 
human complex diseases, as it has a spectrum of diseases similar to that in 
man, and also an advantageous population structure (Karlsson & Lindblad-
Toh, 2008; Sutter et al., 2007; Sutter & Ostrander, 2004). Dogs have a 
history of inbreeding, which has resulted in low levels of genetic variation 
within breeds. The recent breed formation and limited population size has 
also resulted in a high degree of linkage disequilibrium (LD) within breeds 
(Lindblad-Toh et al., 2005a; Sutter et al., 2004), particularly in comparison 
to what is seen in humans (Kruglyak, 1999).  
Certain breeds are known to be predisposed to specific disorders and 
CMT in ESS dogs in Sweden is one such clear example, with 36% of ESS 
dogs in Sweden being affected by CMT (Egenvall et al., 2005). Due to the 
small genetic variation, CMT should have a more homogenous origin 
within a single breed compared to breast cancer in the larger human 
population. This should allow for an easier identification of risk factors 
within a breed. As part of the dog genome sequencing project, a power 
calculation for case-control association within dog breeds was performed, 
suggesting that with 15,000 single nucleotide polymorphisms (SNPs), the 
power to detect a locus with a sample of 100 affected and 100 unaffected 
dogs is 97% for λ = 5 and 50% for λ = 2 (Lindblad-Toh et al., 2005a), if the 
frequency of the associated allele is <20%. This supports the notion that in a 
genetically isolated population, it is relatively easy to identify a specific 
associated haplotype, which is significantly more frequent in cases than in 
controls.  
There are now numerous reports of mapping canine diseases genes, both 
simple and complex, via genome-wide genotyping studies (Wilbe et al., 
2010a), illustrating the broader importance of the dog as a comparative 
model (Breen, 2009). 
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Figure 6. Two population bottlenecks in dog population history, one old and one recent, 
shaped haplotype structure in modern dog breeds. First, the domestic dog diverged from 
wolves 15,000 years ago, probably through multiple domestication events. Within the past 
few hundred years, modern dog breeds were created. Both bottlenecks influenced the 
haplotype pattern and linkage disequilibrium (LD) of current breeds. a | Before the creation 
of modern breeds, the dog population had the short-range LD that would be expected, given 
its large size and the long time period since the domestication bottleneck. b | In the creation 
of modern breeds, a small subset of chromosomes was selected from the pool of domestic 
dogs. The long-range patterns that were carried on these chromosomes became common 
within the breed, thereby creating long-range LD. c | In the short time since breed creation, 
these long-range patterns have not yet been substantially broken down by recombination. 
Long breed haplotypes, however, still retain the underlying short ancestral haplotype blocks 
from the domestic dog population, and these are revealed when one examines chromosomes 
across many breeds. This figure is modified, with permission, from (Lindblad-Toh et al., 
2005b) Nature and (Karlsson & Lindblad-Toh, 2008) Nature Genetics © (2005) Macmillan 
Publishers Ltd. All rights reserved.  
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The question is whether research on CMT can contribute to the 
advancement of knowledge and ultimately the treatment of breast tumors 
affecting women. Research on spontaneous CMT has been performed for 
many decades, but still, canine tumors are not very well established as a 
model for human malignancies. In addition to the high incidence and 
potential of being fatal, similarities with human breast cancer have prompted 
several studies on the incidence and factors affecting the incidence of CMT. 
  Canine mammary carcinomas have epidemiological, clinical, 
morphological and prognostic features similar to those of human breast 
cancer, and are therefore suitable models with naturally occurring tumors 
(Frese, 1985; Chrisp & Spangler, 1980). In both women and dogs, 
mammary tumors develop with age, rarely occurring before 25 and 5 years 
of age, respectively (Cohen et al., 1974). Breast cancer is often familial in 
humans, but a similar hereditary pattern has not been described for 
mammary tumors in dogs, although breed predilections have been reported 
(Egenvall et al., 2005; Cotran, 1994; Dorn et al., 1968b). The development 
of both canine and human mammary tumors is hormone dependent 
(Cotran, 1994; Schneider et al., 1969). Importantly, the biology of CMT 
and human breast cancer is very similar in many aspects. Genes involved in 
tumor development (MET, IGFIR, KIT, mTOR, and p53) have been 
compared between species, and the canine genome showed greater 
similarities to the human DNA sequence compared to the mouse (Paoloni 
& Khanna, 2008; Hoffman & Birney, 2007; Chu et al., 1998), an indication 
that the canine model can be a resource in tumor research, in general. There 
are several examples of similar biology and histology of mammary tumors 
between humans and dogs. For example, mammary sarcomas show the same 
metastasizing patterns in both species (Gullett et al., 2007; Silver & 
Tavassoli, 1998; Fong et al., 1993). Another example is a study that 
evaluated new classifications of human mammary tumors based on gene 
expression profiling data on canine specimens. The classification was 
applicable to canine tumors and could predict outcome (Gama et al., 2008).  
2.8 Comparative oncology 
The value of comparative oncology has been increasingly recognized in the 
field of cancer research, including the identification of cancer-associated 
genes; the study of environmental risk factors, tumor biology, and 
progression; and perhaps most importantly, the evaluation of novel cancer 
therapeutics (Paoloni & Khanna, 2007). Cancer in pets is a spontaneous 
disease. Pet owners, motivated to prolong the quality of life of their animals, 
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frequently seek specialized treatment from veterinary oncologists at private 
veterinary and teaching hospitals. The therapeutic modalities of veterinary 
cancer patients are similar to those of humans, including surgery, 
chemotherapy, radiation therapy, and biotherapy. 
Many factors contribute to the value of these spontaneous tumors as 
relevant models for human cancer. The animals share many environmental 
risk factors, such as housing, food, water, and passive smoking, with their 
owners, suggesting their value as sentinels of disease. Cancers found in 
companion animals share tumor biology and behavior with human cancers, 
and in some cases have identical histology and response rates to 
conventional chemotherapy. In most cases, the prevalence is sufficient for 
clinical trials and biological studies (e.g., mammary tumors, osteosarcoma 
and malignant lymphoma). The size of dogs (and cats) makes multi-modality 
protocols feasible: the lack of “gold standard” treatments allows for early and 
humane testing of novel therapies. Finally, early progression, metastatic 
failure, and shorter life span result in the rapid completion of clinical trials. 
The future of many areas of human and veterinary biomedical research is 
very much interdependent, with one of the closest associations being in 
oncology.  
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3 Aims of the thesis 
The overall aim of this thesis was to further characterize the risk factors for 
the development of canine mammary tumors, using a population of a breed 
at high risk for this disease in Sweden. 
 
The following specific aims were set: 
 
 To study a serum biomarker, thymidine kinase 1 -activity in 
diagnosing, prognosticating and monitoring dogs with canine 
malignant lymphoma, leukemia and solid tumors. 
 
 To describe the clinical and histopathological characteristics of MT 
in a large, clinically well-defined population of ESS female dogs in 
Sweden and to assess the influence of potential risk factors for the 
development of MT and survival.  
 
 To perform a candidate gene association study in CMT, evaluating 
10 human breast cancer genes for association with CMT. 
 
 To study the potential role of MHC class II genes as genetic risk 
factors for the development of CMT. 
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4 Comments on materials and methods 
Overall issues regarding the dogs and the research methods used in studies 
(papers) II-IV are outlined in this section. All the dogs used in these four 
studies were privately owned. For further detailed descriptions, the reader is 
referred to each individual paper. 
4.1 Material and methodological considerations (study I) 
The study population used in Paper I was 95 dogs in total. Thirty healthy 
dogs were included as controls, 7 dogs with mast cell tumors, five with 
osteosarcomas, six with soft tissue sarcomas, 2 with mammary carcinomas, 2 
with thyroid carcinomas, 2 with squamous cell carcinomas, 1 dog with 
transitional cell carcinoma of the bladder, 1 with insulinoma, 29 with 
malignant lymphoma (ML), and 10 with leukemia (LEUK). In total, the 
number of blood samples analyzed was 213 (stored at -200C). Originally, 
230 samples were blinded and randomly collected from a serum tumor bio 
bank. All treatments and sampling of dogs were approved by the Swedish 
Animal Ethics Committee (no. C122/0). The samples originated from a 
serum sample bank containing specimens from dogs mainly with malignant 
lymphoma, sampled between June 2006 and December 2007. 
 Histological/cytological confirmation of diagnosis was procured in all 
tumors. Each dog tumor was staged according to the classification scheme of 
the World Health Organization (WHO). Diagnostic methods employed 
varied, depending on the histologic type of tumor, the anatomic localization 
of the tumor, and the clinical status of the dog. Since new serum samples 
were added during the course of chemotherapy, several of the samples 
eventually proved to come from the same individual, but to have been 
taken on different occasions. Seventeen samples were excluded due to 
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insufficient volume, or because they were from an incorrect specie (n = 10). 
The analyst had no knowledge of the origin of each sample.  
4.2 The Swedish Kennel Club database (studies II-IV) 
The Swedish Kennel Club (SKC) has kept fully computerized records of 
pedigrees and ownership of all pure-breed dogs in Sweden since the year 
1976. In studies II-IV, their register was accessed in order to find and 
contact owners of Swedish ESS dogs of a susceptible age for MT, both dogs 
affected by MT, of any age and any reproductive status (cases), and healthy 
ESS female dogs older than seven years of age and intact or late-spayed 
(spayed >2.5 years of age) (healthy controls). The Swedish Kennel Club 
register was also accessed for pedigree information used for studies III-IV. 
4.3 The Agria Pet Insurance database (studies II-IV) 
The Swedish dog population is unique in that a large proportion of the 
animals are covered by an insurance plan, and that most dogs are not 
neutered. The Swedish animal insurance company Agria (Agria Pet 
Insurance, PO 70306, SE-10723, Stockholm, Sweden) has been shown to 
cover approximately 30-40% of the entire Swedish dog population 
(Egenvall et al., 1999). The database was validated and it was concluded that 
it was acceptable for research purposes (Egenvall et al., 1998). The insured 
dog population in Sweden reflects the general Swedish dog population with 
regard to gender distribution and breed structure. However, the mean age 
of the insured population (5.2 years) is somewhat lower than the general 
Swedish population (5.7 years), although the median ages are equal (5 
years). This is explained by the different age limits that have been applied for 
the different insurance forms. In general, during the study period for Papers 
II-IV, life insurance ended at 10 years of age, and veterinary care insurance 
at 12 years of age. This database was also accessed to obtain additional ESS 
owners and to find additional clinical information on the dogs. 
4.4 The Swedish canine mammary tumor project (studies II-IV) 
A large number of participating dogs with MT (cases) and respective healthy 
dogs (controls) were required for the work of this doctoral research. The 
Swedish canine mammary tumor project was started as a basis for this work 
in April 2005. Since then, peripheral EDTA blood samples, pathological 
reports, and medical records have been collected systematically from dogs 
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diagnosed with MT and healthy dogs of corresponding breeds (ESS, Boxer, 
Doberman, and German shepherd).  
This project is part of the seventh Framework Programme for Research 
and Technological Development of the European Commission, LUPA 
(GA-201370). A broad network of veterinarians, researchers, molecular 
geneticists, bioinformatics specialists, veterinary nurses, breed clubs, and dog 
owners was established. This network was recruited through articles, 
television interviews, lectures, and newsletters. The Swedish Kennel Club, 
the major Swedish dog insurance company, Agria, and various animal 
hospitals and clinics across Sweden made possible for the project to contact 
owners of ESS dogs, both MT-affected dogs and healthy controls. In total, 
peripheral EDTA blood samples from approximately 600 dogs have been 
collected by the author within the project to date, from veterinary animal 
hospitals and veterinary clinics throughout Sweden between 2005 and 2010. 
These samples are stored in a dog genome bio-bank at the department of 
clinical sciences at SLU in -800C until analyzed. The owner of every dog 
involved in the project completed a postal questionnaire, and the 
veterinarian in charge supplied the medical records to the author. Medical 
records and questionnaires for all ESS dogs were reviewed, and owners were 
contacted on several occasions for follow-up information. 
All the blood samples and clinical information collected for Papers II-IV 
were approved by the owners and conformed to the decision of the Swedish 
Animal Ethics Committee (no. C 62/10), and the Swedish Animal Welfare 
Agency (no. 31-1711/10). 
4.5 Clinical information and pathology (studies II-IV) 
The epidemiological data for MT in the Swedish dog population 
(Egenvall et al., 2005) were used to identify a breed at high risk for MT 
(ESS). In these studies we had access to the SKC, as well as the Agria Pet 
Insurance Company. The collaboration in the Swedish canine mammary 
tumor project offers possibilities to access individual dog data with a specific 
diagnosis (CMT) in the pet insurance data-base and link them with ancestral 
background at SKC. Information can be retrieved that enable us to contact 
owners of both dogs with specific phenotypes and related dogs, and to 
access extensive genealogies and informative pedigrees. These features have 
already been used not only to identify birth cohorts but also individual dogs 
to be recruited as cases, as well as controls, and for identification of family 
material in CMT. The same frame is also used for sampling of related and 
unrelated healthy controls in our studies. Using questionnaire information 
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on cases and controls of various phenotypes, we were able to include 
environmental factors in the analyses of genotypes at risk. Identifying 
adequate sample sizes of well-phenotyped dogs from population-based 
epidemiological data, and strict inclusion criteria for the cases, as well as the 
controls, were essential for these studies. Information was collected 
regarding possible risk factors for the development of mammary tumors (age 
of onset, sex, spaying, lactation, and use of contraceptives, diet, pregnancy, 
disease status and family cancer history), including pathology reports and/or 
other clinical diagnostic information. All dogs included in these studies were 
female ESS dogs. All the control dogs were older than seven years, with a 
confirmed absence of CMT based on palpation of the mammary gland 
performed by a veterinarian. The ESS cases were selected based on 
pathology reports, if available, and otherwise based only on physical 
examination data (the presence of a single or multiple nodules within the 
mammary gland). Most of these MT were not surgically excised, or excised 
and not histopathologically evaluated. All the pathological analyses were 
performed by a veterinary pathologist at one of three central laboratories in 
Sweden.  
4.6 Genetic studies (studies III-IV) 
For Papers III and IV genomic DNA was extracted from the blood samples 
using the Qiagen Miniprep extraction kit according to the manufacturer’s 
protocol (Qiagen, Hilden, Germany). Prepared genomic DNA was stored in 
deionized water (stored at -200C). The dogs used in Papers III and IV were 
subdivided into two study populations. In the first population (dataset 1, n = 
192), 99 ESS cases diagnosed with CMT and 92 control dogs older than 
eight years of age were selected. There were 29 cases with malignant 
tumors, 57 cases with benign tumors, all confirmed with histopathology 
performed by a veterinary pathologist at one of three central laboratories, 
and 13 cases for which the pathology report was unknown. All cases and 
controls were selected to be unrelated at the parental level.  
In the replication population (dataset 2, n = 182) the diagnostic criteria 
were less stringent, and fewer dogs with diagnosed malignant disease were 
available. One hundred twenty-one ESS cases were selected based on 
pathology reports, if available, and otherwise based only on physical 
examination data (the presence of a single or multiple nodules within the 
mammary gland). Most of these mammary tumors were not surgically 
excised, or excised and not histopathologically evaluated. Of the 121 cases, 
 
 
37
4 were confirmed as malignant and 39 as benign, by histopathology. Sixty-
one control dogs were available. Siblings were allowed in this population.  
Regarding candidate gene selection and genotyping for Paper III: Ten 
human breast cancer genes (BRCA1, BRCA2, CHEK2, ERBB2, FGFR2, 
LSP1, MAP3K1, RCAS1, TOX3, and TP53) were selected in the present 
study as candidate genes for CMT. Sixty-three SNPs were chosen from the 
2.5 million-SNP map described by Lindblad-Toh et al., (Lindblad-Toh et 
al., 2005b). Four to nine SNPs per candidate gene (63 SNPs in total) were 
selected from the available Dog Genome sequences in the UCSC Genome 
Browser, Dog May 2005 (CanFam2) assembly. The samples were 
genotyped for the 63 SNPs using the iPLEX Gold Mass ARRAY according 
to the manufacturer’s protocol (Sequenom, San Diego, CA, USA). The 
primary genotype data were analyzed using the Typer 4.0 Analyzer User 
Interface software (Sequenom, San Diego, CA, USA) for cluster analysis. 
SNPs with a call rate of >75 % and a minor allele frequency (MAF) of at 
least 5 % were included in each analysis. Samples with a call rate <75% were 
excluded from further analysis. 
The primers for amplification and extension were designed using Mass 
ARRAY Assay Design v.3.1 software. DNA was amplified using PCR, and 
the remaining nucleotide triphosphates were deactivated by phosphatase 
treatment (SAP). A single base primer extension (SBE) step was performed, 
and the allele‐specific extension products of different masses were 
quantitatively analyzed using MALDI‐TOF mass spectrometer. 
Regarding dog leukocyte antigen (DLA) class II typing performed in 
Paper IV: The protocol and locus-specific primers used in this study for 
sequence-based typing of DLA-DRB1, -DQA1, and -DQB1 alleles were 
based on previous studies (Wilbe et al., 2010b; Wilbe et al., 2009; Kennedy, 
2007). The typing method used a polymerase chain reaction (PCR) 
amplification of the genomic DNA, followed by DNA sequencing in one 
direction. All the nucleotide sequences for DLA-DRB1, -DQA1, and -
DQB1 were analyzed using MatchTools and MatchTools Navigator 
(Applied Biosystems, Foster city, CA, USA). These sequences were 
compared to a consensus sequence containing all known polymorphic sites 
and each polymorphic site was analyzed manually. The corrected sequence 
was then matched to a reference sequence library 
(http://www.ebi.ac.uk/ipd/mhc/index.html) using MatchTools, to provide 
the exact matching allele (Wilbe et al., 2010b; Wilbe et al., 2009; Kennedy, 
2007). Haplotypes were first identified in homozygous dogs, and then 
assigned in the heterozygotes and finally, additional haplotypes not found in 
homozygotes were identified. 
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All the lab work and analyses regarding Paper III was performed at the 
Broad Institute of MIT and Harvard, Cambridge, MA, USA. For Paper IV 
all the lab work was performed at the Department of Animal Breeding and 
Genetics, SLU, Uppsala, and the Department of Medical Biochemistry and 
Microbiology (BMC), Uppsala University, Sweden.  
4.7 Statistical methods (studies I-IV) 
For further detailed information of the statistical methods, the reader is 
referred to each individual paper. 
For study I the TK activities were analyzed both before and after log 
transformation (natural log) because of skewed distribution. A plot of the 
difference against the average of the standard (REA) and new measurements 
(Liaison) was performed using the Bland-Altman method (bivariate fit of 
difference) (Bland & Altman, 1995). In addition, Spearman`s rank 
correlation analysis was performed to assess the relationship between the 
different assays. Comparisons between healthy controls, inflammatory 
disease, other tumors, malignant lymphoma (ML), and leukemia (LEUK) 
was done, using one-way analysis (Tukey-Kramer honestly significant 
difference, HSD test), due to unequal-sized groups with unequal variances. 
The α level was set to 0.05. Statistical calculations were performed using the 
JMP® package 7.0 statistical software (SAS Institute, Inc., Cary, NC, USA). 
Values of p < 0.05 were considered indicative of statistical significance. 
For Paper II the data were analyzed statistically using the JMP package 
8.0.2 statistical software (SAS Institute, Inc., Cary, NC, USA). All statistical 
tests were two-tailed. Statistical significance was considered at p < 0.05. 
Descriptive statistics are presented for the distribution of age of onset, tumor 
classification, presence of multiple nodules, ulceration/inflammation of the 
tumor, surgical treatment for MT, evidence of metastasis, tumor recurrence 
or new tumors, pregnancy and mastitis at the time of partum, previous 
hormonal treatments, and reproductive status. Continuous data are 
expressed as median and interquartile range (IQR). The distribution of 
discrete characteristics within cases and controls were tested using Fisher`s 
exact test. Odds ratios were calculated for the different variables comparing 
cases and controls. Continuous dog characteristic data were tested using 
Kruskal–Wallis test. A Kaplan Meier survivor function was used to display 
the age of onset of MT, by reproductive status. 
The effects of dog characteristic data on histological subtype in dogs with 
MT were tested using the same statistical methods as outlined above. Graphs 
of the Kaplan-Meier survivor function were used to display time-to-event 
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curves and estimate the median time to endpoint. Endpoints used were all 
causes of death and death related to MT. Dogs were censored at last date of 
contact, and in the analysis of death directly related to MT, at death 
unrelated to MT. A log-rank test with right censoring was used to assess 
differences between histological subtype groups for survival after diagnosis of 
MT.  
Multivariable Cox Proportional Hazard Models were constructed for 
investigating the effect of potential risk factors for time to onset of MT and 
time of survival after diagnosis (all-causes mortality). The models were built 
in a backward stepwise manner. The analyses started with all risk factors 
included in the model, which were previous pregnancy, hormonal 
treatment, and reproductive status. The variable with the highest p-value 
was eliminated at each step, with reanalysis between steps, until the final 
model was obtained, which was reached when all the remaining variables 
had a p-value <0.05. For the survival analysis of time from diagnosis for all-
causes mortality, the risk factors included, in addition to the above-
mentioned factors, also malignancy and age of onset. The proportional 
hazard assumption was checked by plotting the survival time against the 
different variables. No multivariable model was developed for survival after 
diagnosis for MT-related mortality, because of the low number of events 
and the consequently low number of degrees of freedom. 
For Paper III the association analyses for all comparisons were performed 
with the PLINK software (Purcell et al., 2007) for single chi-square SNP 
association, haplotype association, odds ratios, and MAF. Nominal (raw) 
chi-square and Bonferroni-corrected chi-square p-values were calculated to 
adjust for the multiple testing that arises from evaluating several SNPs or 
haplotypes (47, 48). A Bonferroni-corrected p < 0.05, with correction for 
total SNP number remaining after filtering in each analysis, was considered 
statistically significant, although this likely over-corrects due to the fact that 
most SNPs within a gene likely are linked to each other and therefore are 
not unrelated observations.  
For Paper IV the statistical analyses were performed using VassarStats 
(http://faculty.vassar.edu/lowry/VassarStats.html). A 2 x 2 contingency 
table was used to calculate odds ratios, and p-values for each allele, 
haplotype, and genotype in ESS. For the χ2 test Yates p-value and a 99% 
confidence interval (CI) were used. We analyzed all cases versus all controls 
in data set 1 and data set 2 and together (datasets 1 & 2), to investigate 
whether a single allele, haplotype, or genotype was present at a significantly 
higher or lower frequency in cases compared to controls, and thus associated 
with CMT.  
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5 Main results and discussion 
A detailed discussion of each specific study is given in the respective papers. 
In the general discussion below, the principal features of the investigations 
are summarized. For further details, see Papers I-IV. 
5.1 A serum biochemical tumor marker (TK1) in canine 
malignant lymphoma, leukemia and solid tumors (Paper I) 
The first study in this thesis evaluated the TK1 activity as a potential 
biochemical tumor marker, not only in dogs with response in hematological 
neoplasia (malignant lymphoma, leukemia), but also in those with solid 
tumors. Determinations of TK levels had so far relied on radio enzyme assay 
(REA) and experimental ELISA methods, which limited the clinical use of 
this biomarker, although recent studies in dogs with ML have demonstrated 
its wide potential.  
In this study we also evaluated a new fully automated non-radiometric 
assay, the Liaison TK assay (DiaSorin, Vercelli, Italy). The aim in 
investigating the new Liaison TK assay was both to validate a new non-
radioisotope-based fully automated assay vs. the gold standard TK-REA and 
also to see if the Liaison assay had a higher sensitivity for detecting solid 
tumors.  
The study population in this first study comprised 95 dogs in total. Sera 
from healthy dogs (n = 30), and dogs with leukemia (LEUK) (n = 35), 
malignant lymphoma (ML) (n = 84), non-hematological tumors (n = 50), 
and inflammatory disease (n = 14) were tested using both methods. 
Lymphoma and leukemia samples were available before and during 
chemotherapy. In total, the number of blood samples analyzed was 213. 
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Table 3. Serum thymidine kinase 1 activity is summarized in this table 
 Mean Median Range 
Normal (n = 30) 2.3 1.7 0.4-6.1 
Inflammatory disease (n = 14) 2.1 2.0 0.7-3.0 
Other tumors including CMT (n = 50) 3.3 1.7 0.5-16.2 
ML in complete remission (n = 56) 3.0 2.6 0.5-7.0 
ML out of remission (n = 28) 22.0 18.6 7.2-66.3 
LEUK in remission (n = 11) 21.6 54.0 12.8-26.4 
LEUK out of remission (n = 24) 88.1 57.3 30.7-263.0 
Table 3. Inflammatory diseases, non-hematological neoplasias, and malignant lymphoma in 
complete remission (CR) have TK 1 activity levels not significantly different from those of 
healthy dogs, while the mean TK activity in malignant lymphomas (ML) out of remission 
and leukemias (LEUKs) is 10- to 20- fold higher than the means of the other groups. None 
of the dogs with LEUK reached CR, only partial remission. This shows the clinical benefit of 
monitoring hematological neoplasias with serum TK (s-TK), as well as indicating a high 
specificity of the Liaison assay. 
 
The TK1 levels measured during chemotherapy were different between 
dogs in complete remission and dogs out of remission. A Tukey-Kramer 
analysis showed that all LEUKs and MLs out of remission differed 
significantly from the others groups.  
The Liaison TK assay showed high precision, high sensitivity, and a good 
correlation to the TK REA. Although initially developed for human 
purposes, both the TK REA and the Liaison TK assay are species-
independent, since they measure enzyme activity. This warrants further 
investigations in veterinary medicine. The Liaison TK assay is the first non-
radiometric assay that is able to accurately measure s-TK1 activity in dogs, 
being fully automated for large-scale use, and provides valuable clinical 
information in the treatment and management of canine LEUK and ML, 
with a potential to be further validated in human trials; but, the Liaison assay 
was not effective in detecting solid tumors in the study samples (there were, 
however, only two MT cases in this study). Due to the low sensitivity and 
specificity for the serum biomarker TK1 regarding activity in canine solid 
tumors, another approach was chosen.  
Canine MT was picked as model for further studies from the solid tumor 
group. This choice was based on the high prevalence in Sweden (Egenvall et 
al., 2005), but also because it is considered a good comparative model for 
human breast cancer. To expand the utility of biomarkers, a slightly 
different approach was chosen, as molecular/genetic biomarkers were used 
instead of serum proteins. With this tool, risk factors/predisposing genes 
 
 
43
may be found. At a later stage, sub-populations of dogs having a higher risk 
of developing, for example, CMT, can then be recommended for more 
frequent physical examinations for the presence of tumors and likely have a 
diagnosis as early as possible, enhancing the possibility for a successful 
treatment. This is in contrast to serum biomarkers, which discover tumors 
that are already developing. Moreover, knowledge of predisposing genetic 
risk factors can be beneficial for breeding purposes, to reduce the number of 
susceptible dogs in the high-risk breed.  
This leads us to investigate other biomarker tools, for example to screen 
for potential genetic risk factors involved in the pathogenesis of CMT. 
5.2 Risk factors for CMT in Swedish ESS (Paper II) 
In this case-control study (II), we investigated potential risk factors for 
mammary tumors and survival after MT in the largest uniform population of 
dogs described from one high-risk breed tested so far (488 Swedish ESS 
female dogs in total for study I). We obtained information regarding 299 
MT cases and 189 controls, obtained from questionnaires, pathology reports, 
and medical records of ESS dogs recruited from the Swedish Kennel Club’s 
database. The distribution of various clinical and pathological variables and 
survival times were compared between dogs with or without MT and 
between dogs with malignant or benign tumors.  
5.2.1 Age of onset 
The median age at MT diagnosis was found to be 7 years in study II. This is 
a relatively low age of onset compared to other breeds, and this finding is in 
agreement with a previous study (Egenvall et al., 2005). 
5.2.2 Reproductive status 
Of the 488 dogs in this study, 384 (79%) were sexually intact dogs. The 
majority of dogs spayed in this study were spayed at a relatively late age and 
mainly due to medical reasons, for example, pyometra, with a median age of 
spaying of 6.8 years. Only less than 1% of the dogs in this study were spayed 
early in life as prophylaxis for MT, making it impossible to examine the 
effect of early spaying. More intact female dogs in this study had MT 
compared to spayed dogs. Fifty-three dogs in the case group were spayed 
and 51 dogs in the control group. The OR for MT was 1.7 for intact female 
dogs compared to spayed dogs (p=0.01). We did not find a protective role 
of spaying for survival after diagnosis.  
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5.2.3 Hormonal risk factors 
Only 6% of the population in this study was treated with gestagens to 
prevent estrus and only 5% received aglépristone for pregnancy termination, 
and their mammary glands were not exposed to prolonged hormonal 
stimulation. Failure to show a statistically significant difference in MT 
development in these groups may be due to the small number of dogs 
exposed to hormone treatment. Similarly, there was no influence on the 
development of MT by pregnancy and lactation in the dogs in this study.  
5.2.4 Histopathology 
Benign MT was found in 122 dogs (41%), malignant MT was found in 55 
dogs (18%), and 122 dogs had MT with unknown histopathology (41%). 
The tumor classification in this study revealed that in the group of dogs with 
a histopathology report (n = 177), 68% had benign tumors, and 32%, 
malignant. The higher frequency of benign tumors in this study may be due 
to a relatively low age of onset (median of 7 years); this agrees with findings 
by Sorenmo et al., (2009), which showed that the majority of the dogs in 
her study had only benign tumors and that these dogs were significantly 
younger.  
As a comparison to human breast cancer, similar to what we found in the 
dogs, younger women are more likely to have benign tumors and the risk 
for malignancy increases with age (Miltenburg & Speights, 2008). However, 
Figure 7. Kaplan-Meier function for age of onset of MT by reproductive status (n=299, 
20 missing and 207 censored subjects, which are marked with ticks). Spayed dogs had a 
significantly higher age of onset compare to intact female dogs (log-rank test, p = 0.01) 
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it is possible that some of these benign tumors would have progressed and 
become malignant if opportunity (i.e., time) had been provided.  
One might speculate that early benign tumor development is more easily 
triggered by hormonal effects, but that malignancy is less dependent on 
hormones, due to a loss of steroid dependency for malignant MT (de Las 
Mulas et al., 2005; Millanta et al., 2005). In addition, the genetic 
underpinnings may be slightly different between the early benign and late 
malignant forms. This might be tentatively supported by the fact that 
BRCA1 was more strongly associated in malignant than benign tumors in 
ESS, whereas BRCA2 had similar association to both benign and malignant 
disease (Rivera et al., 2009). Sorenmo et al. recently described that CMT 
progresses from benign to malignant, and that the malignant tumor may be 
the end stage of a histological continuum with clinical and histopathological 
similarities to human breast cancer carcinogenesis (Sorenmo et al., 2009). 
5.2.5 Survival after MT diagnosis 
In the Cox Proportional Hazard Model for survival after diagnosis, a higher 
age of onset was associated with shorter survival times, with a hazard ratio of 
1.67 for each additional year of age (p < 0.001). Benign tumors were 
associated with a more favorable outcome compared to malignant or 
unknown tumors with Hazard ratios of 0.53 and 0.47, respectively (p = 
0.038). 
 
Figure 8. Kaplan-Meier survival function for overall survival time sorted by malignancy (all 
cause of death) (n = 66 deaths, 41 missing and 192 censored subjects, which are marked with 
ticks). Dogs with malignant MT or dogs with unknown MT malignancy had a shorter 
survival after diagnosis than dogs with benign MT, where the endpoint was any cause of 
death (log-rank test, p = 0.021). 
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Figure 9. Kaplan-Meier survival function for overall survival time sorted by malignancy (death 
related to MT). (n = 20 deaths, 41 missing and 231 censored subjects, which are marked 
with ticks). Dogs with malignant MT had a shorter survival after diagnosis than dogs with 
benign MT where the endpoint was death due to MT (log-rank test, p = 0.018). 
 
The survival data shows that dogs with malignant MT had a significantly 
shorter survival time after onset, regardless of whether the endpoint was any 
cause of death (log-rank test and multivariate Cox Proportional Hazard 
analysis), or death due to MT (log-rank test), than dogs with benign MT. 
One simple explanation may be that persistent or recurrent cancer is more 
likely to shorten the dog`s life span, but may not have been recorded as 
related to MT. Furthermore, the knowledge that the dog has MT could also 
affect the tendency for the owner to choose euthanasia, rather than attempt 
treatment in case of development of other disease. A large difference in 
survival time was found with respect to age of onset, a noted risk factor in 
women with breast cancer (Host & Lund, 1986).  
5.3 Identification of genetic risk factors for CMT, using a 
candidate gene approach (Paper III) 
The third study in this thesis is a candidate gene approach to CMT, in 
which we evaluate ten human breast cancer genes (BRCA1, BRCA2, 
CHEK2, ERBB2, FGFR2, LSP1, MAP3K1, RCAS1, TOX3, and TP53) 
for association with CMT. Sixty-three SNPs (4-9 SNPs per gene) were 
genotyped by Sequenom iPLEX in two sets of ESS female dogs (212 CMT 
cases and 143 controls), and association analysis was performed.  
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Table 4. Association of the best single SNP in each gene to CMT risk.  
Gene Best praw 
dataset 1 
Best praw 
dataset 2 
Best praw 
total 
Best pBonf total Odds ratio total 
BRCA2 0.0032 6.7x10-4 3.9x10-6 1.4x10-4 4.24 
BRCA1 0.012 0.18 1.3x10-4 0.0049 3.74 
FGFR2 0.018 0.11 0.0047 0.18 1.88 
TOX3 0.29 0.023 0.014 0.52 1.80 
CHEK2 0.37 0.015 0.034 1.0 1.40 
MAP3K1 0.025 0.54 0.042 1.0 1.43 
LSP1 0.036 0.64 0.11 1.0 1.45 
RCAS1 0.25 0.063 0.16 1.0 1.42 
TP53 0.010 0.80 0.20 1.0 1.23 
ERBB2 0.30 0.33 0.24 1.0 1.45 
Ncases 89 122 212 212 212 
Ncontrols 85  59 143 143 143 
Abbreviations: praw: The best chi-square single SNP p-value obtained for each gene. Nominal association 
(praw< 0.05) is indicated in bold. pBonf: Bonferroni-corrected p-values. Significant association is indicated 
in bold. 
 
Two genes, BRCA1 and BRCA2, were significantly associated with CMT 
(Bonferroni-corrected p = 0.005 and p = 0.0001, respectively) (indicated in 
bold in Table 4). Borderline association was seen for FGFR2. Benign and 
malignant cases were also analyzed separately. Germ line mutations in 
BRCA1 and BRCA2 are thought to account for 5% to 10% of all breast 
cancers in women (Ochiai et al., 2001; Martin et al., 2000), and our results 
suggest that they also predispose to CMT based on candidate gene 
association.  
In this study we were able to detect association to risk factors conferring 
~4-fold increased risk for both BRCA1 and BRCA2 to CMT, using data 
from 212 cases and 143 controls. This is in concordance with previous 
power calculations stating that canine complex traits can be mapped with a 
few hundred dogs (Lindblad-Toh et al., 2005a), and demonstrates the 
advantages of mapping genetic risk factors in dogs compared to humans. 
However, expanding the cohort in our study could possibly generate 
significant associations for additional genes, since the disease frequency is as 
high as ~36% in the ESS breed. This increased disease frequency could be 
caused either by many different risk factors accumulated within the breed or 
by a few risk alleles of very high frequency. The latter notion is supported 
by the high frequency (~90%) of both the BRCA1 and BRCA2 risk alleles 
in the healthy ESS dogs. Despite this high allele frequency, both risk factors 
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confer a ~4-fold increased risk, suggesting a complex etiology of multiple 
strong risk factors for this disease.  
5.4 The potential role of MHC class II as a genetic risk factor in 
CMT (Paper IV) 
In the last study, we investigated the potential role of MHC class II as a 
potential genetic factor for the development of CMT. It has long been 
recognized that genetic susceptibility to cancer may, in part, be due to 
inherited variations in MHC genes (Wu et al., 2002; Sastre-Garau et al., 
1996; Apple et al., 1994; Bidwell et al., 1992; Pellegris et al., 1980). The dog 
leukocyte antigen system (DLA) is believed to play a key role in the tumor 
cell`s escape from immune surveillance. In this study, we evaluated the role 
of MHC class II in controlling the immune response towards CMT tumor 
antigens, and we investigated the role of DLA class II in CMT development 
in dogs. 
We performed sequence-based genotyping of the polymorphic exon 2 of 
DLA-DRB1, -DQA1, and -DQB1 class II loci, using DNA samples from 
363 dogs. Comparison of allele and haplotype distribution between cases 
and controls revealed a statistically significant protective effect in dogs 
carrying the rare haplotype DLA-
DRB1*00101/DQA*100201/DQB*01303 (odds ratio of 0.09, 99% CI 
0.013 - 0.64) and the incidence of CMT. This haplotype confers an ~11-
fold decreased risk for developing the disease and was present in 0.5% of the 
cases (only one dog with benign disease) and 4.8% of the controls (14 
chromosomes). The haplotype includes, not surprisingly, the two rare 
significant DRB1 and DQA1 alleles (DRB1*00101 and DQA1*00201), 
combined with DQB1*01303. The DQB1*01303 allele is common and 
present in 43.1% of the total population (40.1% of the cases and 47.6% of 
the controls) and also found on haplotypes not associated with CMT. Our 
results indicate the DRB1 and DQA1 loci as the major contributors to the 
negative association with only minor influence from DQB1. 
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Table 5. Haplotype frequencies and association with CMT risk in the total population. 
 
 
No 
Haplotype Datasets 1 + 2 (total)  
 
Odds 
Ratio 
  
 
99% CI 
 
DRB1/DQA1/DQB1 
 
Total 
 
Cases 
 
Controls 
 
praw(Yates) 
  % % %   
1 01501/00601/00301 22.6 23.6 21.0 1.16 0.47 0.725-
1.86 
2 00501/00301/00501 9.4 9.9 8.6 1.16 0.66 0.588-
2.288 
3 00101/00201/01303 2.2 0.5 4.8 0.09 0.0002 0.0123-
0.643 
4 01201/00401/01303 34.7 32.8 37.6 0.81 0.21 0.539-
1.219 
5 02001/00601/00301 18.2 20.0 15.5 1.36 0.16 0.817-
2.282 
6 01501/00601/02002 6.2 6.9 5.2 1.35 0.46 0.585-
3.135 
7 02001/00401/01303 3.3 2.8 4.1 0.66 0.42 0.225-
1.912 
8 00601/005011/00701 2.2 3.0 1.0 2.94 0.14 0.558-
15.489 
9 01501/00601/01101 1.0 0.7 1.4 0.50 * 0.069-
3.578 
10 01201/00401/DQB013+017 0.3 0.0 0.7 * * ** 
         Total number (2n) 726 436 290       
* Sample size too small in this category for X2 analysis.  
Significant association 99% CI is indicated in bold.  
 
Mechanistically, it is not known how the DLA association protects against 
CMT development. However, it is worth noting that the detected CMT 
association could be due to the DLA genes in themselves, or explained by 
linkage disequilibrium between the markers analyzed and other protective 
genes. One might speculate that in CMT the immune system plays an 
important role in protecting against tumorigenesis, as specific genetic 
variants may be better suited for facilitating removal of aberrant neoplastic 
cells. This is in concordance with previous studies showing the significance 
of immune surveillance against tumor development and progression 
(Ferguson et al., 2002; Igney & Krammer, 2002). The immune response 
could potentially be directed against mutant self-proteins (Wolfel et al., 
1995) or against proteins expressed in a highly tissue-specific manner in the 
tissue of origin of the tumor (Coulie et al., 1994; Brichard et al., 1993). A 
third category of tumor antigen is represented by proteins that are expressed 
at high levels only in some tumors (Boel et al., 1995; van der Bruggen et al., 
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1991), including melanoma antigen MAGE1 in breast carcinomas (Brasseur 
et al., 1992). The associated haplotype could possibly influence the 
efficiency by which cells present tumor antigens to T-cells. 
Recent research has focused on the functional characteristics and the 
biological significance of MHC class I and II gene product expression and its 
relationship to processing and presentation of tumor antigens, as well as their 
role in anticancer treatment strategies against solid tumors. Feinmesser et al., 
have shown that it is likely that the individual HLA specificities affect both 
the quality and quantity of antitumor immune response (Feinmesser et al., 
2000). Tissue typing in female patients has demonstrated an alteration of 
MHC antigen expression of breast carcinomas, which is usually related to 
prognosis (Concha et al., 1991a; Concha et al., 1991b). It will be interesting 
to see if the expression varies between the protective and other HLA 
haplotypes detected in this study, suggesting a connection to tumor 
surveillance relating to the relative levels of DLA antigens.  
5.5 Some reflections from the author, based on the main 
findings of the thesis 
Activity measurement of thymidine kinase 1 in serum was proven to be 
valuable for staging and monitoring treatment response in hematological 
neoplasia in both dogs and humans. Detecting expression of TK1 in serum, 
and especially tumor tissue, would likely expand usefulness of TK1 in solid 
tumors, as well. This could be clinically relevant, allowing refined grading of 
lymphomas and also solid tumors, including MT. This enzyme has an 
obvious potential as proliferation marker, via both activity measurements 
and protein expressions in the same tumor type. The comparative aspects 
are also obvious with the high homology to human TK1.  
Cancer is a complex disease of all vertebrate species that can be 
considered as a breakdown in cellular homeostasis leading to uncontrolled 
cell division and proliferation, which ultimate leads to a disease state. Cancer 
formation is the phenotypic end result of a whole series of changes that may 
have taken a long period of time to develop. Cancer is a genetic disease, 
involving fundamental changes at the genetic level. Despite major efforts, 
identifying susceptibility genes for common diseases such cancer in humans 
remains extremely difficult. This is likely due to the complexity of the 
underlying causes, including genetic and environmental heterogeneity, and 
gene-by-gene and gene-by-environment interactions. Very large disease 
cohorts genotyped for hundreds of thousands of SNP markers are likely to 
be required to achieve satisfactory power. In order to accelerate the 
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discovery pace, studies that directly target human populations are therefore 
advantageously complemented by studies of more tractable animal models of 
human disease. Until recently, the only widely used model organisms for 
that purpose have been the mouse and rat. Dogs have a number of unique 
features that have the potential to make them a superior genetic system in 
which to study the molecular basis of cancer. 
Changes in oncogenes or tumor suppressor genes may contribute to 
carcinogenesis. Changes or mutations in genes can lead to either a 
stimulatory or inhibitory effect on cell growth and proliferation. The 
stimulatory effects are provided by the proto-oncogenes, where mutations 
of these genes produce positive growth and proliferative signals, leading to 
uncontrolled cellular growth. In contrast, tumor formation can result from a 
loss of inhibitory functions associated with mutation of another class of 
cellular genes called the tumor suppressor genes.  
The high frequency of MT in the Swedish ESS population (36%) 
(Egenvall et al., 2005) might be explained by the inbreeding and 
accumulation of genetic risk factors within the breed. It has been suggested 
that the origin of MT is multifactorial and depends on an interaction 
between multiple major and minor genes and environmental factors. In 
study II we found that reproductive status of the dog appears to significantly 
influence MT development and that age of onset and histological subtype 
affects the survival time after diagnosis. These results were useful in better 
defining the phenotype, which facilitated the genetic analysis. The 
association data obtained in study III indicate that the two suppressor genes 
BRCA1 and BRCA2 are involved in the development of CMT. In their 
wild-type, or non-mutated state, the role of these two tumor suppressor 
genes is to inhibit cellular proliferation and growth. We also identified in 
study IV a rare MHC class II haplotype as a protective genetic factor against 
the development of CMT. One might expect a small number of strong risk 
factors driving up the frequency of MT in the Swedish ESS population, 
such as reproductive status, age of onset, and major genetic risk factors, for 
example, the common genetic variations of BRCA1 and BRCA2 associated 
with MT in this population. Alterations in these genes cause early onset MT 
in women, and it is possible that the ESS has an earlier onset of MT in this 
dog population with similar pathogenesis. The results also suggest a potential 
moderation of the frequency of MT based on the protective MHC 
haplotype in this population. 
 We have performed a genome-wide association (GWA) study using the 
Illumina 100K SNP arrays in 100 cases and 100 controls in Swedish ESS 
dogs and identified several candidate regions. Here we plan to complement 
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this dataset with an additional unrelated 100 cases and 100 controls. In total, 
11 regions have been identified for further examination. Several of these 
contain plausible, but novel, candidate genes. We also plan to replicate the 
candidate genes identified in additional samples by fine mapping in ESS and 
other breeds with increased disease frequency (Boxer, German shepherd and 
Doberman dogs). 
The identification of additional disease-associated markers could permit 
the future development of a genetic test for carriers of MT in these high-
risk breeds. The suspected high frequency of these risk factors for CMT 
development in this breed could be problematic, because removal of 
breeding animals carrying these genetic alterations could create a serious 
genetic bottleneck, which would threaten the viability of the breed. 
Therefore, careful planning and testing is required to increase the frequency 
of the rare protective haplotype found in study IV, while avoiding the 
common alterations in BRCA1 and BRCA2 in these high-risk dog 
populations (study III).  
In addition, further identification of the specific mutation(s) responsible 
for MT could permit further studies of the biological cause underlying 
mammary carcinoma in dogs, eventually allowing exploration of more 
effective therapies. The author also believes that it could be interesting to 
find whether tumors of histological classes are inherited together within a 
family. Our current analysis of a small set of familial cases also suggests that 
different tumor classes can be seen within a family or even a single 
individual. If this is generally true, a more basic predisposing genetic risk 
factor might be present, in addition to genetic risk factors determining 
tumor class. Thus, it would be reasonable to include different histological 
tumor types in the mapping effort to aim to identify more fundamental 
genetic mammary tumor risk factors: If our full analysis shows that different 
histological tumor types are not broadly inherited together, we would focus 
on a particular subset of tumors for the mapping effort.  
It could be also interesting to perform large studies of gene expression in 
clinical samples of spontaneously occurring CMT (and others) in the near 
future. Hopefully, this can also be useful in a comparative fashion to 
enhance the understanding of tumorigenesis and metastatic pathways in both 
dogs and humans. By looking both at the inherited risk factors and the 
effects in expression by whole pathways, one might be able to link certain 
predisposing risk factors to specific changes in the cell. Knowing the faulty 
pathway might allow specific treatment options for each dog based on its 
genetic make-up, a little like personalized medicine. 
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Knowledge of the predisposing genes in dogs is bound to provide insights 
into the pathogenesis of the corresponding human breast cancer and to 
provide novel targets for drug development that would improve both canine 
and human health. 
On the basis of the main findings in this doctoral thesis, the author 
would like to suggests that CMT is an excellent model for human breast 
cancer, indicating that both humans and dogs can benefit from further 
comparative studies and provide a foundation for further studies, which are 
necessary to understand the functional mechanisms whereby this protective 
factor influences the development of mammary tumors in dogs, and possibly 
also in humans. Veterinary oncology will benefit enormously from data 
derived from genomics, and this era will see a huge shift in the ways in 
which companion animal cancer patients are evaluated and consequently 
treated (Breen, 2009). The future seems very promising for veterinary 
clinical oncology, if we succeed in communicating the value of using 
tumors in companion animals as comparative models for human cancers, 
including mammary tumors. 
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6 Conclusions 
Overall, the results of this doctoral thesis contribute new knowledge on 
canine mammary tumors (CMT). More precisely, the main conclusions 
were as follows: 
 
 Serum thymidine kinase 1 was proven to be effective in diagnosing 
and monitoring dogs with hematological neoplasias (lymphoma, 
leukemia), but the Liaison assay was not effective in detecting solid 
tumors. 
 
 Reproductive status is an important risk factor for MT development, 
and age of onset and histological subtype affect the survival time 
after diagnosis of MT affected dogs. 
 
 Two human breast cancer genes, BRCA1 and BRCA2, were 
associated with CMT in ESS dogs. The study suggests that CMT is 
an excellent model for human breast cancer, indicating that both 
humans and dogs can benefit from further comparative studies. 
 
 A rare MHC class II haplotype, DLA 
(DRB1*00101/DQA1*00201/DQB1*01303), was identified as a 
protective genetic factor against the development of CMT in ESS 
dogs. This haplotype confers an ~11-fold decreased risk for 
developing CMT.  
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7 Future research 
New insights have been gained regarding the characteristics of canine 
mammary tumors. More knowledge tends to generate even more questions, 
and that is the case with this thesis, also. There are several research areas that 
have been identified in which studies are ongoing or further research is 
needed: 
 
 Activity measurement of TK1 in serum has been proven to be 
valuable for staging and monitoring treatment response in 
hematological neoplasia in both dogs and humans. Expression of the 
enzyme in serum, and especially tumor tissue, would likely expand 
usefulness of TK1 measurement in solid tumors, as well. Further 
studies are required to investigate the TK1 activity in solid tumors, 
including CMT to investigate its potential clinical utility. 
 
 Further studies are necessary to investigate the role of DLA class II 
in the development of CMT, and to understand the functional 
mechanisms whereby this protective haplotype influences the 
development and malignancy of this disease in ESS dogs, and 
possibly also in humans. 
 
 We have performed a genome-wide association (GWA) study using 
the Illumina 100K SNP arrays in 100 unrelated cases and 100 
unrelated controls in Swedish ESS female dogs and identified several 
candidate regions. Here, we plan to complement this dataset with 
an additional unrelated 100 cases and 100 controls. In total, 11 
regions have been identified for further examination. Several of 
these contain plausible, but novel, candidate genes. We also plan to 
replicate the candidate genes identified in additional samples by fine 
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mapping in ESS and other breeds with increased disease frequency 
(Boxer, German shepherd, and Doberman dogs). We aim also to 
characterize identified susceptibility genes in CMT, to establish 
mechanism and biological significance in dogs and humans. We also 
aim to perform relative risk assessments using the results from the 
candidate gene study, DLA, and the genes resulting from the GWA 
study together, when the exact mutations are known. 
 
 A future goal is to transfer our results to human breast cancer 
cohorts and investigate whether the novel genes and pathways 
identified in the dog are important also in human breast cancer. 
This could provide a unique opportunity to improve prevention, 
diagnosis, and treatment of human breast cancer. 
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8 Populärvetenskaplig sammanfattning 
8.1 Juvertumörer hos hund (kort bakgrund om sjukdomen) 
 
Olika former av cancer är idag en av de vanligaste dödsorsakerna hos 
hundar. Såväl diagnostik som metoder att behandla cancer hos hund och 
katt har utvecklas dramatisk de senaste åren.  
Tumörer i bröstvävnad, som hos hund kallas för juvertumörer, är den 
vanligaste typen av tumör både hos kvinnor och tikar, men sjukdomen är 
ungefär tre gånger vanligare hos hund än människa. Juvertumörer är den 
vanligaste tumörtypen hos icke-kastrerade tikar och den kan även i sällsynta 
fall uppträda hos hanhundar. Framförallt drabbas medelålders och äldre tikar. 
Drygt 50 % av juvertumörerna är godartade och sprider sig inte till andra 
delar av kroppen. Dessa juvertumörer växer långsamt utom under 
löpperioderna då de på grund av påverkan från könshormonerna växer 
snabbare.  
Elakartade tumörer har en potential att sprida sig med uppkomst av 
dottersvulster i andra organ och vävnader som följd. Tiken får ofta tumörer i 
flera juverdelar samtidigt och dessa tumörer kan vara av olika typer. Detta 
gör det svårt att på ett enkelt sätt diagnostisera om tumören är elakartad 
innan en eventuell operation. Det enda säkra sättet att ställa en definitiv 
diagnos är via en mikroskopisk vävnadsundersökning av tumören (biopsi). 
En biopsi ger också viktig information om huruvida man lyckats avlägsna all 
tumörvävnad eller inte. Detta prov kan ge säkrare upplysning om tumörtyp 
och vilken risk för återfall/spridning det finns efter operationen samt info 
om det är lönt att operera tiken igen och ta bort en större bit juvervävnad. 
Juvertumörer behandlas ofta genom ett kirurgiskt ingrepp då hela 
tumören avlägsnas. Prognosen efter operation är individuellt mycket olika 
och beror på tumörens karaktär. Hos människa behandlas ofta nyopererade 
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kvinnor med cellgifter eller strålning. Detta är en behandling som idag 
används mycket sällan hos hund. 
Den enda åtgärden som kan ha verkligt stor betydelse för att undvika att 
hunden får juvertumörer är en tidig kastrering. En tik som kastreras tidigt, 
helst före sitt första löp, får en dramatiskt minskad risk att drabbas av 
juvertumörer senare i livet. För att kastrering av tiken ska skydda mot 
juvertumörer är det viktigt att den utförs tidigt i livet, ju tidigare desto 
bättre. Detta beror på att tumören är beroende av könshormoner, som 
försvinner i och med kastrering. Risken för juvertumör ökar om hunden får 
p-sprutor eller annan hormonell behandling. Varken dräktighet, 
skendräktighet eller kastrering sent i livet påverkar risken för juvertumörer. 
8.2 Hundar som modell för bröstcancerforskning 
Tumörsjukdomar är genetisk komplexa vilket innebär att flera gener ligger 
bakom sjukdomsutvecklingen i kombination med oftast okända 
miljöfaktorer. Genom att hundens hela arvmassa numera är klarlagd har 
möjligheterna till genetisk forskning ökat markant. Hundar är idealiska för 
studier av sjukdomars genetiska bakgrund eftersom individerna inom varje 
hundras är genetiskt mycket lika och därför kan tänkas bära på samma 
genvarianter som ger ökad risk för sjukdom. Eftersom hundar är genetiskt 
mer lika människor än möss som vanligtvis används i forskning är hunden 
ett relevant modelldjur för grundforskning om bröstcancer.  
Juvertumörer är överrepresenterade hos vissa hundraser och en ärftlig 
bidragande orsak misstänks därför. Exempel på hundraser som drabbas oftare 
än andra är engelsk springer spaniel, boxer, schäfer och dobermann. 
Korthårig collie är emellertid en hundras som sällan drabbas. Med 
kunskapen om vilka genetiska komponenter som ligger bakom sjukdomen 
kan bättre diagnostiska och behandlingsmetoder utvecklas som kan komma 
till nytta både för hunden som människan. 
8.3 Sammanfattning av avhandlingsarbetet 
Syftet med avhandlingsarbetet var att öka kunskapen om juvertumörer samt 
att identifiera olika riskfaktorer för utvecklingen av dessa tumörer hos hund. 
För att uppnå dessa mål utfördes fyra studier. 
I den första studien studerades aktiviteten av thymidinkinas (TK) i serum 
hos hundar som drabbat av malignt lymfom, leukemi samt andra tumörer 
bl.a. juvertumörer. Sedan en längre tid har man känt till att framförallt 
hematopoetiska tumörer ger upphov till förhöjda nivåer av proteinet 
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thymidinkinas (TK) i serum hos människa. TK är ett enzym som är involverat 
i DNA-syntesen. Det produceras i celler före celldelning och har visat sig 
vara en god indikator för ökad celldelning. Thymidinkinas frigörs ut till 
cirkulationen när snabbt delande celler dör och cellmembranen går sönder. 
TK är distinkt kopplade till tumörförekomst och grad av malignitet. 
Thymidinkinas är en etablerad celldelningssmarkör som används kliniskt på 
humansidan.  
Vi fann att detta enzym var effektivt för diagnosticering samt 
monitorering av hundar med blodcancer (lymfom, leukemi). Denna studie 
visade dock att detta test var otillräcklig för att kunna användas för att 
upptäcka solida tumörer i det studerade materialet. Detta ledde oss till att 
studera andra potentiella riskfaktorer för utvecklingen av juvertumörer hos 
hund för att kunna ta fram bättre diagnostiska verktyg.  
I de följande tre studierna, användes hundar av rasen Engelsk springer 
spaniel för att studera olika risk faktorer för utveckling av juvertumörer hos 
hund. Vi fann i den andra studien att kastrering minskar risken för 
juvertumörer samt att hundens ålder vid diagnos och typ av juvertumör 
påverkar hundens överlevnadstid efter diagnos. 
 I den tredje och fjärde studien undersöktes olika genetiska riskfaktorer 
för utveckling av juvertumörer hos svenska ESS. I dessa studier försökte vi 
hitta gener som predisponerar för utveckling av juvertumörer. Genom att 
jämföra arvsmassan hos sjuka och friska hundar hittade vi genvarianter som 
påverkar risken för juvertumörer hos ESS. 
I den tredje studien konstaterades för första gången att de sedan tidigare 
kända riskfaktorerna för utveckling av bröstcancer hos människa, BRCA1 
och 2) även utgör riskfaktorer för juvertumörer hos hund.  
I den sista studien undersökte vi om olika varianter av immungenerna 
Major Histocompatibility Complex II (MHC) klass II har någon påverkan 
på förekomst av juvertumörer i ESS hundarna. MHC klass II är en typ av 
antigenpresenterande molekyler som finns på antigenpresenterande celler i 
kroppen. Vår studie visade att en variant av MHC 
(DRB1*00101/DQA1*00201/DQB1*01303) hade en skyddande effekt 
mot juvertumörer.  
Fortsatta studier gällande den genetiska komplexiteten av juvertumörer 
hos hund pågår för närvarande. Genom att förutsättningslöst jämföra 
variation i hela genomet hos sjuka och friska hundar, hoppas vi kunna 
identifiera ej tidigare kända riskfaktorer för uppkomst av juvertumörer. 
Genom att identifiera riskfaktorer för juvertumörer hoppas vi öka förståelsen 
för sjukdomen vilket förhoppningsvis även kan bidra till en ökad förståelse 
av bröstcancer hos människa. 
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